At its 2026 Annual Meeting of Stockholders on June 9, 2026, Humacyte, Inc. stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 350,000,000 to 550,000,000. The meeting also resulted in the election of three Class II directors and the following advisory votes: approval of executive compensation on an advisory basis, approval of annual frequency for future advisory votes on executive compensation, annual ratification of ratification of Pricewaterhouse Coopers LLP as the company's independent registered public accounting firm. Humacyte, Inc. is a biotechnology company that develops human-derived tissue-engineered products.
